The Food and Drug Administration today expanded its approval for remdesivir (Veklury) to include pediatric patients under age 12 who test positive for SARS-CoV-2 and are hospitalized or at high risk of progressing to severe COVID-19. The patient must be at least 28 days old and weigh at least 3 kilograms (6.6 lbs). FDA said the approval is supported by a clinical study of 53 pediatric patients as well as trials in adults, given the similar course of disease in adult and pediatric patients.

The FDA, CDC, NIH, NIAID, WHO ARE CRIME SYNDICATES.

https://www.aha.org/news/news/2022-04-25-fda-approves-first-covid-19-treatment-young-children